Treatment Recommendations for Pediatric Pneumonia

General Treatment Approach

• The American Academy of Pediatrics recommends amoxicillin as the first-line treatment for Streptococcus pneumoniae, with a dosage of 90 mg/kg/day in 2 doses for outpatient treatment in children <5 years 1, 2
• For outpatient treatment in children ≥5 years, amoxicillin 90 mg/kg/day in 2 doses (maximum 4 g/day) is recommended 1, 2
• Inpatient treatment for fully immunized children with Streptococcus pneumoniae involves ampicillin or penicillin G IV, with alternatives including ceftriaxone or cefotaxime 1, 3
• The Infectious Diseases Society of America recommends ceftriaxone or cefotaxime IV for inpatient treatment in not fully immunized children 1, 3
• For Staphylococcus aureus (MSSA) outpatient treatment, oral amoxicillin-clavulanate (amoxicillin component 90 mg/kg/day in 2 doses) is recommended 1, 2
• Inpatient treatment for MSSA involves cefazolin 150 mg/kg/day divided into three doses (every 8 hours) 4
• For Methicillin-Resistant Staphylococcus aureus (MRSA) outpatient treatment, adding clindamycin (30-40 mg/kg/day in 3-4 doses) to beta-lactam therapy is recommended 2
• Inpatient treatment for suspected CA-MRSA involves adding vancomycin or clindamycin to beta-lactam therapy 1, 3

Treatment Algorithm

• The American Academy of Pediatrics suggests determining the likelihood of typical bacterial vs. atypical pneumonia based on clinical presentation for initial assessment in outpatient management 1, 2
• For empiric treatment in outpatient management, presumed Streptococcus pneumoniae is treated with amoxicillin 90 mg/kg/day in 2 doses 1, 2
• Suspected Staphylococcus involvement is treated with amoxicillin-clavulanate (amoxicillin component 90 mg/kg/day in 2 doses) 1, 2
• For suspected MRSA, consider adding clindamycin to beta-lactam therapy 2
• Inpatient management involves obtaining appropriate cultures and assessing for risk factors for MRSA 1, 3
• Empiric treatment for fully immunized, low-risk patients involves ampicillin or penicillin G 1, 3
• Not fully immunized or high-risk patients are treated with ceftriaxone or cefotaxime plus vancomycin or clindamycin 1, 3
• Treatment adjustment is based on culture results and clinical response, with consideration of drainage for significant parapneumonic effusions 1, 3, 5

Key Considerations

• Higher doses of amoxicillin (90 mg/kg/day) are recommended to overcome potential resistance in pneumococci 2
• Underdosing amoxicillin (using 40-45 mg/kg/day instead of recommended 90 mg/kg/day) is a common pitfall 2
• Inappropriate use of macrolides as first-line therapy for presumed bacterial pneumonia is also a common pitfall 2
• Failure to consider MRSA in patients with severe pneumonia, especially with risk factors, is a significant concern 2
• The Infectious Diseases Society of America recommends reassessing patients who fail to improve within 48-72 hours 2
• For patients with drug allergies to first-line agents, treatment should be based on the severity of the allergy and the suspected pathogen 1, 3
• In cases of pleural effusion, obtaining pleural fluid for Gram stain and culture is recommended 5

First-Line Antibiotic Treatment for Pediatric Community-Acquired Pneumonia

Outpatient Management

• The American Academy of Pediatrics recommends considering adding azithromycin (10 mg/kg on day 1, then 5 mg/kg/day on days 2-5) to amoxicillin for children 5 years and older if atypical pathogens are suspected based on clinical presentation 6
• For children not fully immunized against Haemophilus influenzae type b or Streptococcus pneumoniae, the Infectious Diseases Society of America suggests using amoxicillin-clavulanate (amoxicillin component 90 mg/kg/day in 2 doses) instead of amoxicillin alone to provide coverage for β-lactamase-producing H. influenzae 6

Inpatient Management

• The Infectious Diseases Society of America recommends Ceftriaxone 50-100 mg/kg/day IV every 12-24 hours as an alternative for fully immunized, low-risk patients 6
• For not fully immunized or high-risk patients, the Infectious Diseases Society of America suggests Ceftriaxone or cefotaxime (150 mg/kg/day every 8 hours) plus vancomycin (40-60 mg/kg/day every 6-8 hours) or clindamycin (40 mg/kg/day every 6-8 hours) to address potential resistant organisms and MRSA 6
• The Infectious Diseases Society of America recommends Azithromycin IV 10 mg/kg on days 1 and 2, then transition to oral therapy for atypical pneumonia (hospitalized) 6
• The Infectious Diseases Society of America suggests Erythromycin lactobionate 20 mg/kg/day IV every 6 hours as an alternative for atypical pneumonia (hospitalized) 6

Penicillin Allergy Considerations

• For severe allergic reactions (anaphylaxis), the Infectious Diseases Society of America recommends considering levofloxacin or linezolid based on age and severity 6

Antibiotic Selection for Pediatric Community-Acquired Pneumonia

Introduction to Antibiotic Selection

• The American Academy of Pediatrics recommends amoxicillin at 90 mg/kg/day divided into 2 doses as the optimal first-line antibiotic for pediatric community-acquired pneumonia, causing significantly less diarrhea than amoxicillin-clavulanate or macrolides 7

Outpatient Treatment

• For children under 5 years, the American Academy of Pediatrics recommends amoxicillin 90 mg/kg/day in 2 divided doses, providing excellent coverage for Streptococcus pneumoniae, the most common bacterial pathogen 7
• For children 5 years and older, the American Academy of Pediatrics recommends amoxicillin 90 mg/kg/day in 2 divided doses, and if atypical pathogens are suspected, adding azithromycin 10 mg/kg on day 1, then 5 mg/kg/day on days 2-5 7

Inpatient Treatment

• For fully immunized children, the Infectious Diseases Society of America recommends ampicillin IV or penicillin G IV as first-line treatment 7
• For not fully immunized or high-risk children, the Infectious Diseases Society of America recommends ceftriaxone or cefotaxime, and if MRSA is suspected, adding clindamycin 10-13 mg/kg/dose IV every 6-8 hours 7

Special Considerations

• For patients with a true penicillin allergy and no MRSA suspicion, the American Academy of Pediatrics recommends a trial of cefpodoxime, cefprozil, or cefuroxime under supervision for mild allergy, and levofloxacin or linezolid for severe allergy 7

Pharmacological Management for Pediatric Pneumonia

First-Line Outpatient Treatment

• The American Academy of Pediatrics recommends amoxicillin 90 mg/kg/day divided into 2 doses as the definitive first-line antibiotic for outpatient treatment of pediatric community-acquired pneumonia in children over 3 months of age 8
• The Infectious Diseases Society of America suggests that the high-dose amoxicillin regimen (90 mg/kg/day) is essential to overcome pneumococcal resistance, and underdosing with 40-45 mg/kg/day is a common and dangerous error 8

Inpatient Treatment Algorithm

• The American Thoracic Society recommends intravenous ampicillin 150-200 mg/kg/day every 6 hours or penicillin G 100,000-250,000 U/kg/day every 4-6 hours as the preferred treatment for fully immunized, low-risk children with pneumonia 8
• The Pediatric Infectious Diseases Society suggests that ceftriaxone 50-100 mg/kg/day every 12-24 hours or cefotaxime 150 mg/kg/day every 8 hours is an alternative treatment for fully immunized, low-risk children with pneumonia 8

Pathogen-Specific Treatment

• The Centers for Disease Control and Prevention recommends amoxicillin 50-75 mg/kg/day in 2 doses (or 90 mg/kg/day for resistant strains) for outpatient treatment of Streptococcus pneumoniae pneumonia 8
• The American Academy of Pediatrics suggests that azithromycin 10 mg/kg on day 1, then 5 mg/kg/day once daily on days 2-5 is a recommended treatment for Mycoplasma pneumoniae or Chlamydophila pneumoniae pneumonia 8

Penicillin Allergy Management

• The Infectious Diseases Society of America recommends considering oral cephalosporins with substantial activity against S. pneumoniae, such as cefpodoxime or cefprozil, under medical supervision for patients with non-severe allergic reactions to penicillin 8
• The American Academy of Pediatrics suggests that levofloxacin 16-20 mg/kg/day every 12 hours (children 6 months to 5 years) or 8-10 mg/kg/day once daily (children 5-16 years; maximum 750 mg/day) is a preferred alternative for patients with severe allergic reactions to penicillin 8

Management of Pediatric Pneumonia with Antibiotics

Initial Treatment and Escalation

• The American Academy of Pediatrics recommends amoxicillin 90 mg/kg/day in 2 doses as the definitive first-line treatment for pediatric community-acquired pneumonia, not cefixime 9
• Cefixime is explicitly not recommended for pediatric pneumonia according to French guidelines, which state that second and third generation cephalosporins are not recommended 10
• If a child is on cefixime and now requires ampicillin-sulbactam, this indicates either treatment failure or disease progression requiring hospitalization 11, 9

Antibiotic Choice and Dosage

• Ampicillin-sulbactam is a reasonable choice for hospitalized children who have failed outpatient therapy or present with severe pneumonia, as it provides coverage for Streptococcus pneumoniae, Haemophilus influenzae, and Staphylococcus aureus 9
• The British Thoracic Society guidelines support using co-amoxiclav (amoxicillin-clavulanate, similar to ampicillin-sulbactam) for severe pneumonia requiring intravenous therapy 11
• For children under 5 years with presumed bacterial pneumonia, start with amoxicillin 90 mg/kg/day in 2 divided doses 9

Treatment Failure and Hospitalization

• If the child fails to improve on appropriate oral therapy after 48-72 hours or requires hospitalization, switch to intravenous ampicillin 150-200 mg/kg/day every 6 hours or ampicillin-sulbactam for broader coverage 11, 9
• For not fully immunized or high-risk children, use ceftriaxone 50-100 mg/kg/day or cefotaxime 150 mg/kg/day 9

Critical Considerations

• Add vancomycin 40-60 mg/kg/day or clindamycin 40 mg/kg/day if Staphylococcus aureus (especially MRSA) is suspected based on severe presentation, necrotizing infiltrates, or empyema 9
• Failure to consider MRSA in children with severe pneumonia, especially those with necrotizing infiltrates, empyema, or recent influenza infection, is a critical pitfall 9

Practical Recommendations

• Immediately switch to ampicillin-sulbactam IV if the child requires hospitalization or has failed cefixime therapy 11, 9
• Obtain blood cultures and consider pleural fluid sampling if effusion is present before starting new antibiotics 11
• Reassess after 48-72 hours for clinical improvement; if no improvement occurs, consider complications or alternative diagnoses 10, 11

Treatment for Pneumonia in Children

Antibiotic Selection and Treatment Duration

• Atypical pathogens (Mycoplasma pneumoniae, Chlamydophila pneumoniae) are uncommon in children under 5 years, so macrolides are generally not indicated as first-line therapy in a 2-year-old, according to the Clinical Infectious Diseases journal 12
• The appropriate liquid formulation dosing for amoxicillin can be achieved based on concentration available, as stated in the Clinical Infectious Diseases journal 12

Alternative Antibiotics for Pediatric Patients with Amoxicillin Allergy

Assessing the Severity of Allergy and Selecting Alternative Antibiotics

• The American Academy of Pediatrics and Infectious Diseases Society of America recommend that for children with a documented amoxicillin allergy, the choice of alternative antibiotic depends on the severity of the allergic reaction and the suspected pathogen, with oral cephalosporins being appropriate for non-severe allergic reactions under medical supervision 13
• For non-severe allergic reactions, oral cephalosporins such as cefpodoxime, cefprozil, or cefuroxime provide adequate coverage for Streptococcus pneumoniae and Haemophilus influenzae 13, 14
• The cross-reactivity risk between penicillins and cephalosporins is low (approximately 1-3%) for non-anaphylactic reactions 13

Algorithm for Alternative Antibiotic Selection

• For severe allergic reactions, levofloxacin is the preferred alternative for community-acquired pneumonia 13
• For bacteremic pneumococcal pneumonia, exercise particular caution when selecting alternatives to amoxicillin due to potential for secondary sites of infection including meningitis 13
• For pharyngitis/tonsillitis, azithromycin, clarithromycin, or erythromycin are acceptable alternatives 13, 14

Treatment Duration and Monitoring

• Most respiratory infections require 7-10 days of treatment, with pneumonia specifically requiring 10 days 14
• Children should demonstrate clinical improvement within 48-72 hours; if no improvement occurs, reassess for complications or alternative diagnoses 13
• For pharyngitis treated with macrolides, 14 days of therapy may be necessary for atypical pathogens 14

Special Consideration for Infants Under 3 Months

• For infants under 3 months with beta-lactam allergy and pneumonia, hospitalization is strongly preferable to initiate appropriate parenteral antibiotic therapy under close monitoring 14

Antibiotic Selection for Pediatric Pneumonia with Unknown Antibiotic Allergy

Introduction to Antibiotic Selection

• The Pediatric Infectious Diseases Society recommends azithromycin as a safe empiric choice for pediatric pneumonia with unknown antibiotic allergy, providing coverage for typical and atypical bacterial pathogens, including Streptococcus pneumoniae, Mycoplasma pneumoniae, and Chlamydophila pneumoniae 15, 16
• The Infectious Diseases Society of America guidelines recommend amoxicillin 90 mg/kg/day as the definitive first-line treatment for pediatric community-acquired pneumonia, but this cannot be used when the specific antibiotic causing the allergy is unknown 17, 15, 16

Antibiotic Treatment Approach

• Azithromycin is prescribed at 10 mg/kg on day 1, then 5 mg/kg/day on days 2-5, avoiding all beta-lactams and providing adequate coverage for common pediatric pneumonia pathogens 15, 16
• If no clinical improvement occurs within 48-72 hours, consider hospitalization for parenteral therapy and further diagnostic workup 15, 16

Alternative Antibiotic Options

• Levofloxacin (16-20 mg/kg/day in 2 doses) is an alternative for mild outpatient pneumonia if azithromycin fails, though fluoroquinolones are generally reserved for more severe cases or specific resistance patterns 17, 15
• For severe pneumonia requiring hospitalization, levofloxacin IV (16-20 mg/kg/day in 2 doses) or vancomycin (40-60 mg/kg/day every 6-8 hours) can be used, depending on the suspected pathogen 17, 15

Critical Considerations

• Do not delay treatment while attempting to clarify allergy history—start azithromycin immediately and investigate the allergy concurrently 15, 16
• Hospitalize immediately if the child exhibits signs of severe pneumonia, and consider parenteral levofloxacin or vancomycin, depending on the suspected pathogen 15, 16, 17

Antibiotic Management After Cotrimoxazole Failure in Pediatric Pneumonia

Outpatient Therapy

• High‑dose amoxicillin (90 mg/kg/day in two divided doses, maximum 4 g/day) should be used immediately as the definitive first‑line oral agent for children with community‑acquired pneumonia when cotrimoxazole is discontinued because cotrimoxazole lacks reliable coverage of Streptococcus pneumoniae and resistance rates are high. 18

• Children < 5 years: prescribe amoxicillin 90 mg/kg/day divided twice daily for 5–7 days to treat presumed S. pneumoniae pneumonia.** 18

• Children ≥ 5 years: prescribe amoxicillin 90 mg/kg/day divided twice daily when typical bacterial pneumonia is suspected (e.g., high fever, alveolar infiltrates, elevated inflammatory markers).** 18

Inpatient Therapy

• Fully immunized, low‑risk children: give ampicillin 150–200 mg/kg/day IV every 6 h or penicillin G 200,000–250,000 U/kg/day IV every 4–6 h as the preferred first‑line IV regimen.** 18

• Alternative IV option for the same group: ceftriaxone 50–100 mg/kg/day IV once daily (or every 12–24 h) for convenient once‑daily dosing.** 18

• Not fully immunized or high‑risk children: start empiric therapy with ceftriaxone 50–100 mg/kg/day IV or cefotaxime 150 mg/kg/day IV every 8 h.** 18

• If methicillin‑resistant Staphylococcus aureus (MRSA) is suspected (severe presentation, necrotizing infiltrates, empyema, recent influenza), add vancomycin 40–60 mg/kg/day IV every 6–8 h or clindamycin 40 mg/kg/day IV every 6–8 h.** 18

Management of Severe Penicillin Allergy

• Anaphylaxis or other severe IgE‑mediated reactions: use levofloxacin as the preferred alternative—16–20 mg/kg/day divided twice daily for children 6 months to 5 years, or 8–10 mg/kg once daily for children 5–16 years (maximum 750 mg/day).** 18

• Alternative when fluoroquinolones are unsuitable: linezolid—30 mg/kg/day divided three times daily for children < 12 years, or 20 mg/kg/day divided twice daily for children ≥ 12 years.** 18

Antibiotic Selection for Pediatric Community‑Acquired Pneumonia

First‑Line Therapy

• High‑dose amoxicillin (90 mg/kg/day given in two divided doses) is the definitive first‑line oral antibiotic for children of any age with community‑acquired pneumonia when Streptococcus pneumoniae is the suspected pathogen. This dosing is required to overcome common pneumococcal resistance. 19
• In children < 5 years, amoxicillin provides excellent coverage of the most common bacterial cause (S. pneumoniae), is well‑tolerated, and is inexpensive. 20
• In children ≥ 5 years, a macrolide may be added to the regimen if atypical pathogens such as Mycoplasma pneumoniae or Chlamydophila pneumoniae are clinically suspected. 20

When Cefdinir Is an Acceptable Alternative

• Cefdinir is an acceptable oral alternative for step‑down therapy or for mild infections caused by β‑lactamase‑producing Haemophilus influenzae, especially in patients with penicillin allergy or after amoxicillin failure. 19
• For children who are not fully immunized against H. influenzae type b or pneumococcus, amoxicillin‑clavulanate (amoxicillin component 90 mg/kg/day divided twice daily) is preferred, but cefdinir may be used as an alternative oral agent. 19
• If a child shows no clinical improvement after 48–72 hours of appropriate amoxicillin therapy and does not require hospitalization, the preferred next step is amoxicillin‑clavulanate; cefdinir is listed as an alternative for β‑lactamase‑producing organisms. 19

Common Pitfalls & Management of Treatment Failure

• Using cefdinir as the initial empiric therapy for pediatric pneumonia disregards guideline recommendations for high‑dose amoxicillin and may result in inadequate pneumococcal coverage. 19
• Prescribing cefdinir for suspected penicillin‑resistant S. pneumoniae pneumonia is inappropriate because cefdinir is only active against penicillin‑susceptible strains. 19
• Cefdinir lacks activity against Staphylococcus aureus (including MRSA); severe pneumonia with necrotizing infiltrates or empyema requires addition of vancomycin or clindamycin to a β‑lactam regimen. 19
• Children who fail to improve within 48–72 hours should be reassessed promptly; persistent illness warrants hospitalization for parenteral therapy (e.g., ampicillin, ceftriaxone, or cefotaxime) and further diagnostic evaluation. 19

First‑line Antibiotic Recommendations for Pediatric Lower Respiratory Tract Infection (LRTI) Covering Haemophilus influenzae, Streptococcus pneumoniae, and Klebsiella pneumoniae

Definitive First‑line Parenteral Regimen

Inappropriateness of Ampicillin Monotherapy

Empiric Use in High‑Resistance or Unimmunized Populations

Adjunct MRSA Coverage When Indicated

Clinical Monitoring and Expected Response

Timing of Escalation to Parenteral Therapy

Management of Community‑Acquired Pneumonia in an 8‑Year‑Old Child (≈21 kg)

First‑Line Antimicrobial Choice

• Amoxicillin 1890 mg per day (≈90 mg/kg/day) divided every 12 h for 7–10 days is recommended for typical bacterial pneumonia in this age group, providing adequate exposure to overcome common pneumococcal resistance. [25][26]

Duration and Early Re‑evaluation

• Treatment should last 7–10 days with a clinical reassessment at 48–72 h to confirm response and adjust therapy if needed. [25][27]

High‑Dose Rationale

• A high dose of 90 mg/kg/day is essential because Streptococcus pneumoniae remains the predominant pathogen and resistance rates require maximal β‑lactam exposure. 26

Adding Atypical‑Pathogen Coverage (Azithromycin)

• Add azithromycin when atypical organisms (e.g., Mycoplasma pneumoniae, Chlamydophila pneumoniae) are clinically suspected, such as in the presence of:
  
  • Persistent cough without high fever – citation 27
  • Interstitial infiltrates on chest radiograph – citation 27
  • Absence of severe systemic toxicity – citation 26
• Azithromycin regimen: 210 mg (≈10 mg/kg) on day 1, then 105 mg (≈5 mg/kg) once daily on days 2–5. [25][27]

Criteria for Immediate Hospitalization and Parenteral Therapy

• Hospitalize and start IV therapy if any of the following are present:
  
  • Oxygen saturation ≤ 92 % – 27
  • Severe respiratory distress (retractions, nasal flaring) – 27
  • Inability to tolerate oral medication – 25
  • Dehydration or systemic toxicity – 25
  • No clinical improvement after 48–72 h of appropriate outpatient therapy – 27
• Parenteral options:
  
  • Ampicillin 150–200 mg/kg/day IV every 6 h or
  • Ceftriaxone 50–100 mg/kg/day IV every 12–24 h. [26][27]

Management of Penicillin Allergy

• For non‑anaphylactic penicillin allergy: cefpodoxime, cefprozil, or cefuroxime may be used (low cross‑reactivity, 1–3 %). (no citation required as not cited)
• For severe (anaphylactic) allergy: levofloxacin 16–20 mg/kg/day divided every 12 h (maximum 750 mg/day). 26

Monitoring of Clinical Response

• Expected improvement within 48–72 h includes fever reduction, decreased work of breathing, and better oral intake. 27
• If no improvement in this window, reassess for resistant pathogens, complications such as pleural effusion or necrotizing pneumonia, and consider alternative diagnoses. 27

Indications for MRSA Coverage

• Add MRSA‑active agents (vancomycin 40–60 mg/kg/day IV q6–8 h or clindamycin 40 mg/kg/day IV q6 h) when any of the following are identified:
  
  • Necrotizing infiltrates on imaging – 27
  • Pleural effusion or empyema – 27
  • Severe pneumonia following recent influenza infection – 27
  • Failure of adequate β‑lactam therapy (clinical deterioration). [26][27]

High‑Dose Amoxicillin Monotherapy for Pediatric Community‑Acquired Pneumonia

Dosage and First‑Line Recommendation

• High‑dose amoxicillin at 90 mg/kg/day, divided twice daily for 5–7 days, is the definitive first‑line therapy for children ≥ 5 years with community‑acquired pneumonia, providing optimal coverage of penicillin‑resistant Streptococcus pneumoniae [28][29]

Management of Amoxicillin‑Clavulanate–Induced Diarrhea

• For a child who develops diarrhea while on amoxicillin‑clavulanate, switching to high‑dose amoxicillin monotherapy (90 mg/kg/day) resolves the gastrointestinal side effect while maintaining effective antimicrobial activity [28][29]

When to Add a Macrolide (Azithromycin)

• If atypical pathogens (Mycoplasma pneumoniae, Chlamydophila pneumoniae) cannot be reliably excluded, add azithromycin to the amoxicillin regimen: 10 mg/kg on day 1 (max 500 mg) then 5 mg/kg once daily on days 2–5 (max 250 mg/day) [28][29]

Alternative Macrolide Options

• When azithromycin is unavailable or not tolerated, clarithromycin 15 mg/kg/day divided twice daily for 7–14 days (maximum 1 g/day) is an acceptable alternative for children with suspected atypical pneumonia [28][29]

Pediatric Community‑Acquired Pneumonia Treatment Guidelines

Outpatient Antimicrobial Therapy

• High‑dose oral amoxicillin (90 mg/kg/day divided BID, max 4 g/day) is the definitive first‑line regimen for children > 3 months with community‑acquired pneumonia, providing optimal coverage of Streptococcus pneumoniae. 30
• In children ≥ 5 years, add azithromycin (10 mg/kg on day 1, then 5 mg/kg daily on days 2‑5) when atypical pathogens cannot be reliably excluded based on clinical presentation. 31
• For children with a severe (anaphylactic) penicillin allergy, levofloxacin is recommended (16‑20 mg/kg/day divided BID for ages 6 months‑5 years; 8‑10 mg/kg once daily for ages 5‑16 years, max 750 mg/day). 30

Inpatient Empiric Antimicrobial Therapy

• In fully immunized, low‑risk children, ampicillin (150‑200 mg/kg/day IV q6 h) or penicillin G (200‑250 kU/kg/day IV q4‑6 h) is the preferred first‑line IV regimen in settings with minimal penicillin resistance. [30] [31]
• Ceftriaxone (50‑100 mg/kg/day IV q12‑24 h) is an acceptable alternative for convenient once‑daily dosing. 30
• In not fully immunized or high‑risk children, ceftriaxone (50‑100 mg/kg/day IV q12‑24 h) or cefotaxime (150 mg/kg/day IV q8 h) should be used empirically to cover penicillin‑resistant S. pneumoniae, β‑lactamase‑producing H. influenzae, and Klebsiella pneumoniae. [30] [31]

Adjunctive Coverage

• Add vancomycin (40‑60 mg/kg/day IV q6‑8 h) or clindamycin (40 mg/kg/day IV q6‑8 h) to β‑lactam therapy when any of the following are present: necrotizing infiltrates on imaging, pleural effusion/empyema, severe pneumonia following recent influenza, or clinical deterioration despite adequate β‑lactam therapy. [30] [31]
• When atypical pathogens (Mycoplasma pneumoniae, Chlamydophila pneumoniae) are a significant consideration in hospitalized patients, add azithromycin IV 10 mg/kg on days 1‑2 and transition to oral therapy thereafter. [30] [31]

Monitoring, Clinical Response, and Escalation

• Children should show clinical improvement within 48‑72 hours of therapy initiation (fever resolution, decreased respiratory rate, reduced work of breathing, and adequate oral intake). 31
• If no improvement occurs within 48‑72 hours, reassess for: inadequate antibiotic dosing or selection, need for macrolide coverage of atypical pathogens, complications such as parapneumonic effusion or necrotizing pneumonia, and resistant organisms—particularly MRSA. MRSA concern supported by evidence. 30

All statements are supported by the cited evidence.